001     873655
005     20210130004502.0
024 7 _ |a 10.1021/acschemneuro.9b00558
|2 doi
024 7 _ |a 2128/24627
|2 Handle
024 7 _ |a altmetric:74090514
|2 altmetric
024 7 _ |a pmid:31939658
|2 pmid
024 7 _ |a WOS:000515195800005
|2 WOS
037 _ _ |a FZJ-2020-00886
082 _ _ |a 540
100 1 _ |a Fatafta, Hebah
|0 P:(DE-Juel1)176262
|b 0
245 _ _ |a Role of Oxidized Gly25, Gly29, and Gly33 Residues on the Interactions of Aβ 1–42 with Lipid Membranes
260 _ _ |a Washington, DC
|c 2020
|b ACS Publ.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1585727496_27240
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Oxidative stress is known to play an important role in the pathogenesis of Alzheimer's disease. Moreover, it is becoming increasingly evident that the plasma membrane of neurons plays a role in modulating the aggregation and toxicity of Alzheimer's amyloid-β peptide (Aβ). In this study, the combined and interdependent effects of oxidation and membrane interactions on the 42 residues long Aβ isoform are investigated using molecular simulations. Hamiltonian replica exchange molecular dynamics simulations are utilized to elucidate the impact of selected oxidized glycine residues of Aβ42 on the interactions of the peptide with a model membrane comprised of 70% POPC, 25% cholesterol, and 5% of the ganglioside GM1. The main findings are that, independent of the oxidation state, Aβ prefers binding to GM1 over POPC, which is further enhanced by the oxidation of Gly29 and Gly33 and reduced the formation of β-sheet. Our results suggest that the differences observed in Aβ42 conformations and its interaction with a lipid bilayer upon oxidation originate from the position of the oxidized Gly residue with respect to the hydrophobic sequence of Aβ42 involving the Gly29-XXX-Gly33-XXX-Gly37 motif and from specific interactions between the peptide and the terminal sugar groups of GM1.
536 _ _ |a 553 - Physical Basis of Diseases (POF3-553)
|0 G:(DE-HGF)POF3-553
|c POF3-553
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Poojari, Chetan
|0 P:(DE-Juel1)140589
|b 1
700 1 _ |a Sayyed-Ahmad, Abdallah
|0 0000-0003-2415-8403
|b 2
700 1 _ |a Strodel, Birgit
|0 P:(DE-Juel1)132024
|b 3
700 1 _ |a Owen, Michael
|0 P:(DE-Juel1)161571
|b 4
|e Corresponding author
773 _ _ |a 10.1021/acschemneuro.9b00558
|g p. acschemneuro.9b00558
|0 PERI:(DE-600)2528493-9
|n 4
|p 535-548
|t ACS chemical neuroscience
|v 11
|y 2020
|x 1948-7193
856 4 _ |y Published on 2020-01-15. Available in OpenAccess from 2021-01-15.
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/873655/files/Autorenmanuskript%20Role%20of%20Oxidized%20Gly25%2C%20Gly29%2C%20and%20Gly33%20Residues%20on%20the%20Interactions%20of%20A%CE%B21%E2%80%9342%20with%20Lipid%20Membranes.pdf
856 4 _ |u https://juser.fz-juelich.de/record/873655/files/acschemneuro.9b00558.pdf
|y Restricted
856 4 _ |y Published on 2020-01-15. Available in OpenAccess from 2021-01-15.
|x pdfa
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/873655/files/Autorenmanuskript%20Role%20of%20Oxidized%20Gly25%2C%20Gly29%2C%20and%20Gly33%20Residues%20on%20the%20Interactions%20of%20A%CE%B21%E2%80%9342%20with%20Lipid%20Membranes.pdf?subformat=pdfa
856 4 _ |x pdfa
|u https://juser.fz-juelich.de/record/873655/files/acschemneuro.9b00558.pdf?subformat=pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:873655
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)176262
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)132024
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)161571
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACS CHEM NEUROSCI : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21